Hepatocellular carcinoma tumour burden score to stratify prognosis after resection

被引:106
作者
Tsilimigras, D. I. [1 ]
Moris, D. [1 ]
Hyer, J. M. [1 ]
Bagante, F. [1 ,4 ]
Sahara, K. [1 ]
Moro, A. [1 ]
Paredes, A. Z. [1 ]
Mehta, R. [1 ]
Ratti, F. [5 ]
Marques, H. P. [6 ]
Silva, S. [6 ]
Soubrane, O. [7 ]
Lam, V. [8 ]
Poultsides, G. A. [3 ]
Popescu, I. [10 ]
Alexandrescu, S. [10 ]
Martel, G. [11 ]
Workneh, A. [11 ]
Guglielmi, A. [4 ]
Hugh, T. [9 ]
Aldrighetti, L. [5 ]
Endo, I. [12 ]
Sasaki, K. [2 ]
Rodarte, A. [2 ]
Aucejo, F. N. [2 ]
Pawlik, T. M. [1 ]
机构
[1] Ohio State Univ, Dept Surg, Wexner Med Ctr, 395 W 12th Ave,Suite 670, Columbus, OH 43210 USA
[2] Cleveland Clin, Digest Dis Inst, Cleveland, OH 44106 USA
[3] Stanford Univ, Stanford, CA 94305 USA
[4] Univ Verona, Dept Surg, Verona, Italy
[5] Osped San Raffaele, Milan, Italy
[6] Curry Cabral Hosp, Dept Surg, Lisbon, Portugal
[7] Beaujon Hosp, AP HP, Dept Hepatobiliopancreat Surg, Clichy, France
[8] Westmead Hosp, Dept Surg, Sydney, NSW, Australia
[9] Univ Sydney, Sch Med, Sydney, NSW, Australia
[10] Fundeni Clin Inst, Dept Surg, Bucharest, Romania
[11] Univ Ottawa, Dept Surg, Ottawa, ON, Canada
[12] Yokohama City Univ, Sch Med, Yokohama, Kanagawa, Japan
关键词
SURGICAL RESECTION; LIVER RESECTION; GUIDELINES; SURVIVAL; SELECTION; INVASION; SURGERY; SIZE; TOOL; HCC;
D O I
10.1002/bjs.11464
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background Although the Barcelona Clinic Liver Cancer (BCLC) staging system has been largely adopted in clinical practice, recent studies have emphasized the need for further refinement and subclassification of this system. Methods Patients who underwent hepatectomy with curative intent for BCLC-0, -A or -B hepatocellular carcinoma (HCC) between 2000 and 2017 were identified using a multi-institutional database. The tumour burden score (TBS) was calculated, and overall survival (OS) was examined in relation to TBS and BCLC stage. Results Among 1053 patients, 63 (6 center dot 0 per cent) had BCLC-0, 826 (78 center dot 4 per cent) BCLC-A and 164 (15 center dot 6 per cent) had BCLC-B HCC. OS worsened incrementally with higher TBS (5-year OS 77 center dot 9, 61 and 39 per cent for low, medium and high TBS respectively; P < 0 center dot 001). No differences in OS were noted among patients with similar TBS, irrespective of BCLC stage (61 center dot 6 versus 58 center dot 9 per cent for BCLC-A/medium TBS versus BCLC-B/medium TBS, P = 0 center dot 930; 45 versus 13 per cent for BCLC-A/high TBS versus BCLC-B/high TBS, P = 0 center dot 175). Patients with BCLC-B HCC and a medium TBS had better OS than those with BCLC-A disease and a high TBS (58 center dot 9 versus 45 per cent; P = 0 center dot 005). On multivariable analysis, TBS remained associated with OS among patients with BCLC-A (medium TBS: hazard ratio (HR) 2 center dot 07, 95 per cent c.i. 1 center dot 42 to 3 center dot 02, P < 0 center dot 001; high TBS: HR 4 center dot 05, 2 center dot 40 to 6 center dot 82, P < 0 center dot 001) and BCLC-B (high TBS: HR 3 center dot 85, 2 center dot 03 to 7 center dot 30; P < 0 center dot 001) HCC. TBS could also stratify prognosis among patients in an external validation cohort (5-year OS 79, 51 center dot 2 and 28 per cent for low, medium and high TBS respectively; P = 0 center dot 010). Conclusion The prognosis of patients with HCC varied according to the BCLC stage but was largely dependent on the TBS.
引用
收藏
页码:854 / 864
页数:11
相关论文
共 35 条
  • [1] Trends in the Mortality of Hepatocellular Carcinoma in the United States
    Beal, Eliza W.
    Tumin, Dmitry
    Kabir, Ali
    Moris, Dimitrios
    Zhang, Xu-Feng
    Chakedis, Jeffery
    Washburn, Kenneth
    Black, Sylvester
    Schmidt, Carl M.
    Pawlik, Timothy M.
    [J]. JOURNAL OF GASTROINTESTINAL SURGERY, 2017, 21 (12) : 2033 - 2038
  • [2] Liver resection for HCC outside the BCLC criteria
    Bhandare, Manish S.
    Patkar, Shraddha
    Shetty, Nitin
    Polnaya, Ashwin
    Kulkarni, Suyash
    Dusane, Rohit R.
    Shrikhande, Shailesh V.
    Goel, Mahesh
    [J]. LANGENBECKS ARCHIVES OF SURGERY, 2018, 403 (01) : 37 - 44
  • [3] Heterogeneity of Patients with Intermediate (BCLC B) Hepatocellular Carcinoma: Proposal for a Subclassification to Facilitate Treatment Decisions
    Bolondi, Luigi
    Burroughs, Andrew
    Dufour, Jean-Francois
    Galle, Peter R.
    Mazzaferro, Vincenzo
    Piscaglia, Fabio
    Raoul, Jean Luc
    Sangro, Bruno
    [J]. SEMINARS IN LIVER DISEASE, 2012, 32 (04) : 348 - 359
  • [4] X-tile: A new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization
    Camp, RL
    Dolled-Filhart, M
    Rimm, DL
    [J]. CLINICAL CANCER RESEARCH, 2004, 10 (21) : 7252 - 7259
  • [5] Survival Analysis of Single Large (&gt;5 cm) Hepatocellular Carcinoma Patients: BCLC A versus B
    Cho, Yuri
    Sinn, Dong Hyun
    Yu, Su Jong
    Gwak, Geum Youn
    Kim, Ji Hoon
    Yoo, Yang Jae
    Jun, Dae Won
    Kim, Tae Yeob
    Lee, Hyo Young
    Cho, Eun Ju
    Lee, Jeong-Hoon
    Kim, Yoon Jun
    Yoon, Jung-Hwan
    [J]. PLOS ONE, 2016, 11 (11):
  • [6] Prospective validation of the Barcelona Clinic Liver Cancer staging system
    Cillo, U
    Vitale, A
    Grigoletto, F
    Farinati, F
    Brolese, A
    Zanus, G
    Neri, D
    Boccagni, P
    Srsen, N
    D'Amico, F
    Ciarleglio, FA
    Bridda, A
    D'Amico, DF
    [J]. JOURNAL OF HEPATOLOGY, 2006, 44 (04) : 723 - 731
  • [7] Predictors of microvascular invasion in patients with hepatocellular carcinoma who are candidates for orthotopic liver transplantation
    Esnaola, NF
    Lauwers, GY
    Mirza, NQ
    Nagorney, DM
    Doherty, D
    Ikai, I
    Yamaoka, Y
    Regimbeau, JM
    Belghiti, J
    Curley, SA
    Ellis, LM
    Vauthey, JN
    [J]. JOURNAL OF GASTROINTESTINAL SURGERY, 2002, 6 (02) : 224 - 232
  • [8] European Assoc Study Liver, 2018, J HEPATOL, V69, P182, DOI 10.1016/j.jhep.2018.03.019
  • [9] Development and Validation of a New Prognostic System for Patients with Hepatocellular Carcinoma
    Farinati, Fabio
    Vitale, Alessandro
    Spolverato, Gaya
    Pawlik, Timothy M.
    Huo, Teh-la
    Lee, Yun-Hsuan
    Frigo, Anna Chiara
    Giacomin, Anna
    Giannini, Edoardo G.
    Ciccarese, Francesca
    Piscaglia, Fabio
    Rapaccini, Gian Lodovico
    Di Marco, Mariella
    Caturelli, Eugenio
    Zoli, Marco
    Borzio, Franco
    Cabibbo, Giuseppe
    Felder, Martina
    Sacco, Rodolfo
    Morisco, Filomena
    Biasini, Elisabetta
    Foschi, Francesco Giuseppe
    Gasbarrini, Antonio
    Baroni, Gianluca Svegliati
    Virdone, Roberto
    Masotto, Alberto
    Trevisani, Franco
    Cillo, Umberto
    [J]. PLOS MEDICINE, 2016, 13 (04)
  • [10] Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine
    Fujiwara, Naoto
    Friedman, Scott L.
    Goossens, Nicolas
    Hoshida, Yujin
    [J]. JOURNAL OF HEPATOLOGY, 2018, 68 (03) : 526 - 549